Published in Cancer Res on May 02, 2012
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 2.89
BAP1 and cancer. Nat Rev Cancer (2013) 2.23
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling. Am J Pathol (2013) 1.61
Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ (2013) 1.25
HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol (2013) 1.18
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood (2014) 1.15
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ (2013) 1.12
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer (2013) 1.06
Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC Cancer (2014) 1.01
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients. Clin Cancer Res (2016) 0.96
Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol (2016) 0.95
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis (2013) 0.93
TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. Cell Mol Immunol (2013) 0.93
The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of Mesothelium. Nutrients (2016) 0.92
CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res (2012) 0.92
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cell Mol Immunol (2016) 0.89
Aspirin's Active Metabolite Salicylic Acid Targets High Mobility Group Box 1 to Modulate Inflammatory Responses. Mol Med (2015) 0.87
Malignant mesothelioma: development to therapy. J Cell Biochem (2014) 0.85
HMGB1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer (2013) 0.85
The Role of Toll-Like Receptors in Hematopoietic Malignancies. Front Immunol (2016) 0.83
Therapeutic implications of immunogenic cell death in human cancer. Front Immunol (2014) 0.83
The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review. PLoS One (2014) 0.83
Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605). Int J Mol Sci (2016) 0.83
Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma. Cancer Gene Ther (2014) 0.83
Killing cancer cells, twice with one shot. Cell Death Differ (2014) 0.82
Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis (2015) 0.81
Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure. Bioanalysis (2015) 0.81
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med (2015) 0.81
Activated amelogenin Y-linked (AMELY) regulation and angiogenesis in human hepatocellular carcinoma by biocomputation. Oncol Lett (2013) 0.80
Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Sci Rep (2016) 0.79
HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget (2016) 0.79
Chemokine interaction with synergy-inducing molecules: fine tuning modulation of cell trafficking. J Leukoc Biol (2015) 0.79
Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene (2016) 0.79
Investigating palygorskite's role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity. J Toxicol Environ Health B Crit Rev (2016) 0.78
Different Toll-Like Receptor Expression Patterns in Progression toward Cancer. Front Immunol (2014) 0.78
Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma. J Cell Mol Med (2015) 0.78
Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells. Mol Cancer (2017) 0.78
Clinical and prognostic significance of high-mobility group box-1 in human gliomas. Exp Ther Med (2014) 0.77
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. Oncoimmunology (2015) 0.76
Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis. Oncoimmunology (2016) 0.76
Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Sci Rep (2016) 0.76
Paradoxical Role of High Mobility Group Box 1 in Glioma: A Suppressor or a Promoter? Oncol Rev (2017) 0.76
Emerging role of HMGB1 in lung diseases: friend or foe. J Cell Mol Med (2016) 0.75
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know. Eur J Cardiothorac Surg (2014) 0.75
FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. J Transl Med (2017) 0.75
HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget (2017) 0.75
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes Cancer (2016) 0.75
Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases. Dis Markers (2017) 0.75
Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene (2016) 0.75
Cyclin-dependent kinase 1(CDK1)-mediated Mitotic Phosphorylation of the Transcriptional Co-repressor Vgll4 Inhibits its Tumor-suppressing Activity. J Biol Chem (2017) 0.75
CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity. Cell Signal (2017) 0.75
The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget (2017) 0.75
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Transl Lung Cancer Res (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol (2005) 11.57
DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2006) 10.73
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2003) 8.34
High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med (2000) 7.38
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
HMG-1 as a mediator of acute lung inflammation. J Immunol (2000) 4.78
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med (2007) 3.72
Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood (2002) 3.70
New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J (2001) 3.04
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol (2004) 2.75
Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol (2006) 2.57
Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol (2012) 2.56
Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery (1999) 2.44
HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 2.35
High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol (2004) 2.32
Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol (2008) 2.20
TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A (2006) 2.14
Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A (2000) 1.91
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol (2002) 1.82
Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A (2011) 1.80
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol (2006) 1.73
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer (2007) 1.61
HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am J Physiol Cell Physiol (2005) 1.51
Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res (2011) 1.47
Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol (2008) 1.43
Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog (2011) 1.34
Health experts concerned over India's asbestos industry. Lancet (2010) 1.26
Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep (2003) 1.26
HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J Leukoc Biol (2006) 1.16
High mobility group box 1 protein, a cue for stem cell recruitment. Biochem Pharmacol (2004) 1.16
Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation. FEBS Lett (1997) 1.10
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res (2008) 1.06
Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol Rep (2003) 1.01
Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth. Genes Cancer (2011) 0.87
Asbestos exposure induces MCP-1 secretion by pleural mesothelial cells. Exp Lung Res (2000) 0.87
Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli. Biochem J (2005) 0.83
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J (2003) 6.46
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep (2002) 4.76
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med (2010) 4.61
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med (2005) 4.11
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol (2007) 3.12
A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood (2007) 3.09
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med (2008) 2.97
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg (2008) 2.93
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 2.89
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med (2012) 2.79
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol (2004) 2.75
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol (2012) 2.56
HMGB proteins and gene expression. Curr Opin Genet Dev (2003) 2.55
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
HMGB1: guiding immunity from within. Trends Immunol (2005) 2.42
A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-kappaB-dependent gene activity. EMBO J (2006) 2.41
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res (2005) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol (2011) 2.26
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 2.26
BAP1 and cancer. Nat Rev Cancer (2013) 2.23
Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol (2008) 2.20
TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A (2006) 2.14
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappaB activation. J Cell Biol (2007) 1.98
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev (2006) 1.94
Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res (2010) 1.94
High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol (2015) 1.93
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
The MSP receptor regulates alpha6beta4 and alpha3beta1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell (2003) 1.91
The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J (2002) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res (2007) 1.89
The development and deployment of Common Data Elements for tissue banks for translational research in cancer - an emerging standard based approach for the Mesothelioma Virtual Tissue Bank. BMC Cancer (2008) 1.88
Mammographic density and breast cancer risk: the multiethnic cohort study. Am J Epidemiol (2005) 1.86
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
Cellular and molecular facets of keratinocyte reepithelization during wound healing. Exp Cell Res (2004) 1.84
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
Sustained oscillations of NF-kappaB produce distinct genome scanning and gene expression profiles. PLoS One (2009) 1.81
Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A (2011) 1.80
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med (2012) 1.76
Sublobar resection: a movement from the Lung Cancer Study Group. J Thorac Oncol (2010) 1.74
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74
MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer (2010) 1.74
Ethnic differences in quality of life among early breast and prostate cancer survivors. Psychooncology (2002) 1.73
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol (2006) 1.73
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
The dual role of IL-10. Trends Immunol (2003) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One (2010) 1.66
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg (2003) 1.66
Simian virus 40 infection in lymphoproliferative disorders. Lancet (2003) 1.63
Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol (2005) 1.63
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer (2007) 1.61
Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling. Am J Pathol (2013) 1.61